Specialty
Laboratory Medicine & Pathology devices
Last checked: Nov 19, 2026Source: openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
2,933
510(k), De Novo and PMA
Decisions, last 36 months
789
Recruiting device trials
7
Industry sponsored
Adverse event reports
1,212,790
Received Nov 1, 2025 to Nov 19, 2026
Narrower views
Latest FDA decisions
The 8 newest. A specialty is the FDA review panel, or a list of product codes for a narrower view.
Siemens Healthcare Diagnostics, Inc.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
K262172 · Decided Nov 6, 2026 · 133 days after receipt
Device type: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System (PCH) · Laboratory Medicine & Pathology
K262789 · Decided Nov 4, 2026 · 90 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
K262807 · Decided Nov 4, 2026 · 89 days after receipt
Device type: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (LON) · Laboratory Medicine & Pathology
K262842 · Decided Nov 4, 2026 · 84 days after receipt
Device type: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays (PMN) · Laboratory Medicine & Pathology
- VITEK PRO510(k)
K262683 · Decided Nov 3, 2026 · 95 days after receipt
Device type: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (LON) · Laboratory Medicine & Pathology
Siemens Healthcare Diagnostics Products, Ltd.
K260400 · Decided Nov 2, 2026 · 269 days after receipt
Device type: System, Test, Radioallergosorbent (Rast) Immunological (DHB) · Laboratory Medicine & Pathology
Maine Molecular Quality Controls, Inc.
K263232 · Decided Oct 30, 2026 · 44 days after receipt
Device type: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays (PMN) · Laboratory Medicine & Pathology
FDA decisions per month
Last 36 months, by decision date and pathway.
- 510(k)
- De Novo
- PMA
View as table
| Month | 510(k) | De Novo | PMA |
|---|---|---|---|
| Dec 23 | 29 | 0 | 1 |
| Jan 24 | 12 | 1 | 1 |
| Feb 24 | 16 | 1 | 0 |
| Mar 24 | 29 | 1 | 1 |
| Apr 24 | 23 | 1 | 1 |
| May 24 | 30 | 0 | 4 |
| Jun 24 | 18 | 1 | 0 |
| Jul 24 | 18 | 1 | 2 |
| Aug 24 | 20 | 2 | 2 |
| Sep 24 | 9 | 0 | 0 |
| Oct 24 | 20 | 1 | 3 |
| Nov 24 | 14 | 0 | 2 |
| Dec 24 | 18 | 1 | 0 |
| Jan 25 | 28 | 0 | 2 |
| Feb 25 | 25 | 0 | 0 |
| Mar 25 | 16 | 1 | 0 |
| Apr 25 | 19 | 0 | 1 |
| May 25 | 21 | 2 | 1 |
| Jun 25 | 25 | 1 | 0 |
| Jul 25 | 13 | 1 | 2 |
| Aug 25 | 25 | 0 | 4 |
| Sep 25 | 21 | 2 | 2 |
| Oct 25 | 21 | 0 | 1 |
| Nov 25 | 16 | 0 | 2 |
| Dec 25 | 18 | 1 | 2 |
| Jan 26 | 18 | 0 | 1 |
| Feb 26 | 13 | 0 | 3 |
| Mar 26 | 16 | 0 | 0 |
| Apr 26 | 26 | 0 | 0 |
| May 26 | 17 | 0 | 6 |
| Jun 26 | 19 | 0 | 2 |
| Jul 26 | 20 | 0 | 3 |
| Aug 26 | 18 | 1 | 3 |
| Sep 26 | 25 | 0 | 2 |
| Oct 26 | 32 | 1 | 0 |
| Nov 26 | 7 | 0 | 0 |
Recruiting device trials
Industry-sponsored device trials that are recruiting now, most recently updated first.
Cadence NeuroscienceNot on our public-company list
NCT06424977 · 40 participants (planned) · Start Nov 1, 2026 · Primary completion May 1, 2028
Device: Biomarker Targeted Stimulation (BTS) · For: Epilepsy
Sites: Palo Alto, California; Rochester, Minnesota; Fort Worth, Texas · 4 sites in all
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPivotal-lookingRecruiting
OSE ImmunotherapeuticsNot on our public-company list
NCT06472245 · 363 participants (planned) · Start Dec 3, 2024 · Primary completion May 1, 2028
Device: NGS HLAA2 assay · For: Patients With Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Encino, California; Los Angeles, California · 207 sites in all
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyPivotal-lookingRecruiting
Boehringer IngelheimNot on our public-company list
NCT07544654 · 390 participants (planned) · Start Jul 10, 2026 · Primary completion Dec 13, 2029
Device: Ventana DLL3 RxDx assay · For: Extrapulmonary Neuroendocrine Cancer (epNEC)
Sites: Scottsdale, Arizona; Duarte, California; San Francisco, California · 170 sites in all
- An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseRecruiting
Voyager TherapeuticsNot on our public-company list
NCT07764146 · 18 participants (planned) · Start Sep 3, 2026 · Primary completion Apr 28, 2029
Device: Anti-AAV9 Total Antibody (TAb) Assay · For: Alzheimer s Disease
Sites: Maitland, Florida; Orlando, Florida
Endomagnetics Ltd.Not on our public-company list
NCT03796559 · 65 participants (planned) · Start Jun 13, 2019 · Primary completion Dec 2026
Device: Magseed Marker · For: Breast Cancer; Axillary Lymph Nodes
Sites: Houston, Texas · 2 sites in all
HepQuant, LLCNot on our public-company list
NCT07009132 · 75 participants (planned) · Start Aug 4, 2025 · Primary completion Dec 2026
Device: Dual cholate clearance assay · For: Fontan; Right Heart Failure
Sites: Philadelphia, Pennsylvania
How new technology gets paid for
Recent Medicare coverage decisions that touch this specialty.
Reports received
1,212,790
Received Nov 1, 2025 to Nov 19, 2026. Includes 846 of another or unstated type.
Malfunction reports
1,132,618
93% of reports
Injury reports
78,918
6.5% of reports
Death reports
408
0.0% of reports
Adverse event reports received per month
By the date FDA received each report. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Nov 25 | 53,256 | 4,295 | 29 | 0 |
| Dec 25 | 62,540 | 6,289 | 29 | 1 |
| Jan 26 | 113,296 | 5,465 | 36 | 5 |
| Feb 26 | 54,101 | 5,185 | 23 | 0 |
| Mar 26 | 60,527 | 5,708 | 33 | 2 |
| Apr 26 | 87,139 | 7,060 | 34 | 2 |
| May 26 | 89,547 | 7,133 | 25 | 1 |
| Jun 26 | 101,110 | 7,552 | 36 | 1 |
| Jul 26 | 95,590 | 7,783 | 53 | 121 |
| Aug 26 | 175,753 | 7,570 | 49 | 177 |
| Sep 26 | 165,750 | 7,836 | 35 | 212 |
| Oct 26 | 74,009 | 7,042 | 26 | 324 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types with the most reports
Widely used device types get more reports. This is not a ranking of safety.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.